Navigation Links
Cobalis Corp. Receives $415,000 First Purchase Order from Major Retail Pharmacy for PreHistin® Allergy Defense Formula
Date:1/12/2011

IRVINE, Calif., Jan. 12, 2011 /PRNewswire/ -- Cobalis Corp., (Pink Sheets: CLSC) makers of PreHistin® Allergy Defense Formula, announced today that they have received a $415,000 opening purchase order via the Direct EDI ordering and invoicing system from one of the nation's two leading chain pharmacies, as well as opening orders from several other national and regional healthcare product distributors and retailers; thus signaling the launch of PreHistin®'s national retail marketing campaign.  The aggregate purchase orders call for delivery of over 25,000 boxes of PreHistin® to some 5,000 pharmacies nationwide in the country's top allergy cities.  Delivery of PreHistin® will commence in mid-February to enable PreHistin® to appear on pharmacy shelves in time for the spring allergy season.

Cobalis plans to support its retail sales program by launching 30-second and 60-second branded television commercials in top market cities announcing that PreHistin® is now available at these pharmacies.   These commercials will feature Dr. Paul Ratner, MD - one of the country's leading allergists and clinical researchers - as saying: "PreHistin® can help allergy sufferers reset their body's normal response to seasonal and year-round allergens – which is no allergic response at all," distinguishing PreHistin® from current after-the-fact antihistamines.  PreHistin® does not require a prescription, is 100% non-drowsy and has no known side effects.

Martin Marion, Cobalis' CEO said, "We are extremely proud that one of the nation's most prestigious and respected healthcare retailers has selected PreHistin® Allergy Defense Formula to be part of its line of consumer healthcare pharmacy products.  We will put a major effort behind supporting these retailers, driving consumers to the pharmacies, and to bring the PreHistin® message aggressively to the more than 60 million Americans who suffer needlessly from seasonal and year-round allergies.  This is the game-changer Cobalis has been preparing for, transitioning Cobalis from a research and development company to a fundamental revenue-generating operation."

Cobalis expects to quickly expand its retail presence for PreHistin® Allergy Defense Formula to other significant retailers coast-to-coast and to build a significant brand presence for PreHistin®.  In addition, Cobalis plans to unveil its new online marketing website network within the next few weeks, which will be supported by an aggressive SEO and SEM campaign.

ABOUT PREHISTIN® ALLERGY DEFENSE FORMULAPreHistin® Allergy Defense Formula is a unique, patented cobalamin complex product that helps rebalance the immune system to lower allergen antibody IgE levels, and regulate the release of symptom-linked histamine which is linked to the onset of symptoms such as sneezing, itchy watery eyes, runny nose and nasal congestion.  PreHistin® is a cherry-flavored lozenge that is dissolved under the tongue and then swallowed twice a day for 21 to 30 days, usually before the pollen season.  PreHistin® has no known side effects, is 100% non-drowsy, and has no contraindications with any other medications.  In clinical trials on thousands of allergy sufferers, PreHistin® was shown to be safe and effective in reducing nasal symptoms.

ABOUT COBALIS CORP.—PREHISTIN®Cobalis Corp. is a specialty pharmaceutical, nutraceutical and preventive healthcare product development and marketing company.  Its flagship product, PreHistin® Allergy Defense Formula, "The World's FIRST Pre-Histamine", is designed to mitigate overproduction of IgE levels and restore a normal response to seasonal and year-round indoor and outdoor allergens.  PreHistin® is now available without prescription for both long-term and daily use.

For PreHistin® product information please visit www.PreHistin.com or call toll free 1-877-4POLLEN (1-877-476-5536).  For additional company information please visit the corporate website at www.Cobalis.comCONTACTCobalis Corp.16795 Von Karman, Suite 200Irvine, CA 92606949-260-0123 (pacific time)Chas Radovich, PresidentMartin Marion, CEOinfo(at)cobalis(dot)com
'/>"/>

SOURCE Cobalis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cobalis Corp. Provides Marketing Update Conference Call for Investors
2. Cobalis Corp. Announces Second Update Conference Call for Investors on October 5, 2010
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
5. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
8. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
9. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
10. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
11. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  A new study by ... the use of opioid therapy to treat chronic pain ... likelihood of more harmful consequences, including death. ... and Zankhana Mehta , M.D., authored the study ... chronic opioid therapy. The study was published in the ...
(Date:12/8/2016)... 2016 Mederi Therapeutics Inc . hat die behördliche Zulassung ... für gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast ... of Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... 2016 According to the research report, ... is expected to be worth US$9.7 bn by the ... Between the forecast years of 2016 and 2024, the global ... The leading players operating in the global diabetes injection pens ... plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research reports ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into law ... in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition ... to the study, medical payments per claim in California decreased 4 percent in 2013 ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and the Affordable Care Act. Dr. Botelho advocates for the mass media launching ... movement gives people ongoing opportunities to share their unfortunate experiences; such a movement ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... financial planning services from offices headquartered in Little Rock, has initiated a charity ... According to the National Foundation to End Senior Hunger, Arkansas ranks first in ...
(Date:12/8/2016)... ... 08, 2016 , ... The Dan Carlisle Agency, an Alabama-owned ... is announcing the launch of a charity drive to raise support and awareness ... and children in Birmingham has grown steadily since the 1980’s, and the Pathways ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coppin Insurance Agency, an insurance ... in and around the Cape Coral area, is embarking on a charity drive with ... Southwest Florida. , The Harry Chapin Food Bank of Southwest Florida works to provide ...
Breaking Medicine News(10 mins):